Watch this presentation to learn • Overview of the SNDS and the key working practices to access the database and ongoing SNDS developments • Similarities and differences between SNDS and other claims databases • Strengths and opportunities for HTAs and market access in Europe through case studies • Stakeholder perspectives: current and potential benefits to … Continued
Author: Jim Gallagher
PRINCETON, N.J.—May. 6, 2021– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2021. Highlights: Revenue was $66.7 million, representing growth of 16% over the first quarter of 2020. Net income was $1.1 million, compared to a net income of $1.0 million in … Continued
First-of-its-kind software predicts likelihood of off-target safety issues that could impede clinical progress PRINCETON, NJ – May 4, 2021, Certara, Inc. (Nasdaq: CERT), the global leader in biosimulation, today announced the launch of its Secondary Intelligence™ software, the first and only software that quantitatively predicts the risk of adverse effects and safety issues derived from … Continued
Oligonucleotide therapies— nucleic acid polymers with the potential to treat or manage a wide range of diseases— are experiencing tremendous growth in the pharmaceutical industry. But, performing the needed PK/PD and clinical pharmacology assessments to optimize the safety and efficacy of investigational oligonucleotide candidates and gain regulatory approval can be challenging. It’s enough to make … Continued
PRINCETON, N.J.— April 30, 2021 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will be participating in the BofA Securities 2021 Virtual Health Care Conference. William Feehery, CEO, and Andrew Schemick, CFO, are scheduled to present on Tuesday, May 11, 2021 at 2:45 p.m. ET. A live webcast will … Continued
The state of gene therapy faces much uncertainty as recent regulatory and clinical setbacks have raised questions about its promise. With only two gene therapies FDA-approved for rare diseases to date, the path to developing these medicines is still a difficult one. This presentation exploreed how the biopharma industry can overcome development challenges in the … Continued
June 17, 2021, Thu 11:15 AM EDT Learn about the role of clinical pharmacology and model-informed drug development in aiding the development and approval of drugs for rare and neglected diseases. Examples of applications of these principles to global health will also be presented.